EGFR and neoplasm: Although the resistant clones were difficult to completely eradicate, the subclonal competition theory between sensitive and resistant clones may have implications in tumor control at the macro level, which provides opportunities for receiving potentially beneficial anti-EGFR treatment for a subset of initial or acquired RAS-mutant metastatic CRCs.